Brain-calming neuropeptide fragment (Galanin 1-16, mouse/rat/porcine)

What this is

Galanin (1-16) is the N-terminal half of galanin, a 29- to 30-residue neuropeptide that the body uses for signaling in the brain, spinal cord, and gut. Even though it is just the first 16 amino acids of the parent hormone, this short fragment binds the galanin receptor and reproduces many of galanin's effects — making it a useful tool for studying the system. The stored sequence GWTLNSAGYLLGPHAI is the rodent/porcine galanin (1-16) form; the human equivalent differs at position 14, where rodents and pig have isoleucine and humans have valine (Webling 2012). The fragment was first chemically synthesized and characterized in the late 1980s as a way to probe which parts of galanin actually do the work at its receptor (Fisone 1989).

History

The full-length galanin peptide was first isolated from porcine intestine in the early 1980s. By the end of the decade, researchers wanted to know whether the active "business end" of the molecule lived in the N-terminus or the C-terminus. Fisone and colleagues (PNAS 1989) addressed this directly: they prepared galanin (1-16) by solid-phase synthesis and by enzymatic cleavage of the full peptide with endoproteinase Asp-N, then tested it against the receptor binding sites galanin uses. The fragment competed with radiolabeled galanin in rat forebrain and spinal cord autoradiography and, in ventral hippocampus membranes, bound with an IC50 of roughly 3 nM — close enough to full-length galanin that the N-terminal half clearly held the active pharmacophore (Fisone 1989). That finding kicked off two decades of work using N-terminal fragments and analogs to map the galanin receptor system, which eventually turned out to include three distinct receptors: GalR1, cloned from a Bowes melanoma cDNA library by Habert-Ortoli and colleagues (PNAS 1994); GalR2 (Wang 1997; Bloomquist 1998); and GalR3 (Smith 1998).

What it does

In tissue, galanin (1-16) does what full galanin does: it engages galanin receptors and dampens neuronal signaling. In the original characterization, the fragment inhibited muscarinic-agonist-stimulated breakdown of inositol phospholipids in hippocampal slices, mirroring the effect of full-length galanin (Fisone 1989). Across the broader galanin system, receptor activation generally couples to Gi/Go proteins, reducing cAMP and shifting downstream signaling in ways that tend to suppress excitability (Habert-Ortoli 1994; Webling 2012). The 1-16 fragment binds GalR1 with affinity comparable to the longer parent peptide, which is why it has been used as a research probe for galanin pharmacology and for dissecting which residues at the N-terminus matter most for receptor recognition (Webling 2012; Freimann 2015).

Mechanism

Galanin receptors are class A G-protein-coupled receptors. GalR1 and GalR3 signal predominantly through Gi/Go, lowering cAMP and activating inwardly rectifying potassium currents; GalR2 also couples to Gq/11, raising intracellular calcium and engaging phospholipase C signaling (Habert-Ortoli 1994; Wang 1997; Bloomquist 1998; Smith 1998; Webling 2012; Gopalakrishnan 2021). The N-terminal residues of galanin — covered entirely by galanin (1-16) — carry the primary binding determinants for these receptors; truncation studies and structure-activity reviews place the high-affinity recognition motif within this stretch (Fisone 1989; Webling 2012; Freimann 2015). At GalR1 specifically, galanin (1-16) displaces radiolabeled galanin from high-affinity hippocampal sites with an IC50 of approximately 3 nM (Fisone 1989). Because the fragment lacks the C-terminal portion of the parent peptide, it has been used to ask whether the C-terminus contributes selectivity among GalR1/2/3 — a question reviews continue to revisit as receptor-subtype-selective ligands are developed (Webling 2012; Freimann 2015).

Evidence

• Human: No clinical trials of galanin (1-16) itself. The fragment is used as a research tool and as a starting point for galanin-receptor-targeted analog design, not as a therapeutic candidate in human studies. Reviews discuss the galanin system as a potential target in neurological disease, including epilepsy, pain, and mood disorders, but the clinical work has focused on receptor-subtype-selective analogs rather than the native 1-16 fragment (Freimann 2015).
• Animal / ex vivo: In rat ventral hippocampus membranes, galanin (1-16) displaces radiolabeled galanin with an IC50 of ~3 nM and inhibits muscarinic-stimulated inositol phospholipid breakdown in hippocampal slices (Fisone 1989). Receptor autoradiography on rat forebrain and spinal cord confirms binding to the same sites engaged by full-length galanin (Fisone 1989).
• In vitro: The mapping of galanin receptor subtypes used cloned human and rat GalR1, GalR2, and GalR3 in heterologous expression systems (Habert-Ortoli 1994; Wang 1997; Bloomquist 1998; Smith 1998). Subsequent SAR work — summarized in Webling (2012) and Freimann (2015) — has profiled N-terminal galanin fragments and analogs across all three receptors.

Known effects

Effects below are documented for galanin (1-16) specifically or for the galanin system at the receptors it engages. Evidence-level tags reflect what the dossier supports.

• GalR1 binding (high affinity) — Demonstrated in rat hippocampus (Fisone 1989).
• Inhibition of muscarinic-stimulated inositol phospholipid turnover in hippocampus — Demonstrated ex vivo (Fisone 1989).
• Receptor-subtype mapping tool — Used widely in cloned-receptor pharmacology and SAR (Webling 2012; Freimann 2015).
• Neurological-disease relevance (parent system) — Galanin receptors are discussed as potential targets in epilepsy, neuropathic pain, depression, and anxiety, based on the parent peptide's CNS biology. The therapeutic interest sits at the receptor-system level, not the 1-16 fragment as a drug (Freimann 2015).

Regulatory status

• US / EU: Not an approved drug. Galanin (1-16) is a research peptide; no marketed product, no FDA or EMA approval. Galanin-receptor-targeted therapeutics that have advanced toward clinical work are subtype-selective analogs, not the native 1-16 fragment.
• WADA: Not specifically listed. Galanin-receptor agonists are not currently named on the prohibited list.

Related peptides

• Galanin (parent peptide) — The 29-residue (rodent) / 30-residue (human) full-length neuropeptide from which the 1-16 fragment is derived. The 1-16 fragment retains most of the receptor binding affinity at GalR1 (Fisone 1989; Webling 2012).
• Galanin-receptor subtype-selective analogs — A family of synthetic analogs developed to distinguish GalR1, GalR2, and GalR3 pharmacology; reviewed in Webling (2012) and Freimann (2015). These analogs are the route through which the galanin system is being pursued therapeutically.